Global Information
회사소개 | 문의 | 비교리스트

봉입체근염(IBM) : 파이프라인 리뷰

Inclusion Body Myositis (IBM) - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 271829
페이지 정보 영문 70 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


봉입체근염(IBM) : 파이프라인 리뷰 Inclusion Body Myositis (IBM) - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 70 Pages

봉입체근염(IBM)은 염증성근병증의 일종으로, 근육 및 근육에 혈액을 공급하는 혈관 등 관련 조직의 염증을 일으킵니다. 손목 및 손가락, 대퇴관계 등의 근력이 서서히 저하합니다.

봉입체근염(IBM) 치료제의 개발 상황에 대해 조사분석했으며, 파이프라인 제품의 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 관한 정보를 정리하여 전해드립니다.

목차

서론

봉입체근염(IBM) 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 치료제 : 기업별
  • 치료제 : 대학/연구기관별
  • 개발중인 제품 : 기업별
  • 개발중인 제품 : 대학/연구기관별

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Acceleron Pharma Inc
  • KPI Therapeutics Inc
  • Milo Biotechnology LLC
  • Nobelpharma Co Ltd
  • Orphazyme ApS
  • Ultragenyx Pharmaceutical Inc

약제 개요

개발 휴지중인 프로젝트

제조 중지가 된 제품

제품 개발 마일스톤

  • 주목 정보와 프레스 릴리스

부록

도표

KSA 17.06.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Inclusion Body Myositis (IBM), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by AAVogen Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Abcuro Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Alzheon Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Cleave Therapeutics Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Kv1.3 Therapeutics, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Leadiant Biosciences Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Milo Biotechnology LLC, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co Ltd, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Orphazyme A/S, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Dormant Projects, H1 2020
  • Inclusion Body Myositis (IBM) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Inclusion Body Myositis (IBM), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis - Pipeline Review, H1 2020, provides an overview of the Inclusion Body Myositis (Musculoskeletal Disorders) pipeline landscape.

Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Inclusion Body Myositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1, 5 and 1 respectively.

Inclusion Body Myositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Inclusion Body Myositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Inclusion Body Myositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Inclusion Body Myositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (Musculoskeletal Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Inclusion Body Myositis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Inclusion Body Myositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Inclusion Body Myositis (IBM) - Overview
    • Inclusion Body Myositis (IBM) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Inclusion Body Myositis (IBM) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development
    • AAVogen Inc
    • Abcuro Inc
    • Alzheon Inc
    • Cleave Therapeutics Inc
    • Kv1.3 Therapeutics
    • Leadiant Biosciences Inc
    • Milo Biotechnology LLC
    • Nobelpharma Co Ltd
    • Orphazyme A/S
    • PhaseBio Pharmaceuticals Inc
    • Ultragenyx Pharmaceutical Inc
  • Inclusion Body Myositis (IBM) - Drug Profiles
    • ABC-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aceneuramic acid ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALZ-507 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arimoclomol citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVGN-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalazatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DEXM-74 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene therapy To Activate Follistatin For Duchenne Muscular Dystrophy, Becker Muscular Dystrophy And Inclusion Body Myositis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PB-1023 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit VCP/p97 for Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UX-001P - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Inclusion Body Myositis (IBM) - Dormant Projects
  • Inclusion Body Myositis (IBM) - Discontinued Products
  • Inclusion Body Myositis (IBM) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 11, 2020: CytRx highlights recently published data of its licensee Orphazyme A/S Phase 2 trial of Arimoclomol in the treatment of Sporadic Inclusion Body Myositis (sIBM)
      • Dec 18, 2019: Orphazyme's arimoclomol receives US fast track designation in sporadic inclusion body myositis
      • May 02, 2019: CytRx Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme
      • Apr 29, 2019: CytRx highlights enrollment completion in phase 2/3 clinical trial of Sporadic Inclusion Body Myositis conducted by Arimoclomol Licensee Orphazyme
      • Apr 23, 2019: Orphazyme's Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled
      • Apr 25, 2018: New Data Supports Dalazatide from Kv 1.3 Therapeutics as a Potential Therapy for Inclusion Body Myositis
      • Dec 14, 2017: Orphazyme Assumes Sponsorship of Phase II/III sIBM Trial
      • Nov 07, 2017: Orphazyme Receives Orphan Drug Designation To Arimoclomol For Inclusion Body Myositis From The U.S. FDA
      • Aug 22, 2017: Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy
      • Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union
      • Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy
      • Mar 24, 2016: Arimoclomol shows promise in protein misfolding disease
      • Mar 23, 2016: New drug shows promise against muscle wasting disease
      • Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency
      • May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q